Evidence map›Paper›PMID 35123465›Full record

ArticleBMC pulmonary medicine2022

Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.

Xianghua Ye, Jinsong Yang, Justin Stebbing, Ling Peng

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Radiation Recall Pneumonitis withDiseases (Basel, Switzerland) · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Xianghua Ye *Department of Radiotherapy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Jinsong Yang *Department of Radiotherapy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Justin StebbingDivision of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.
Ling PengCancer Center, Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang Province, China. drpengling@hotmail.com.ORCID http://orcid.org/0000-0002-1359-4982
Zhejiang University · CNImperial College London · GBZhejiang Provincial People's Hospital · CN

Funding

Medical Science Research Foundation of Health Bureau of Zhejiang Province 2022KY545Zhejiang Traditional Chinese Medicine Administration 2022ZA021
6 · The paper itself

Abstract

backgroundRadiation recall pneumonitis (RRP) is unpredictable but associated with severe radiation damage in previously irradiated fields. Chemotherapy and targeted drugs have been reported to contribute to RRP. Here we report a case of a patient with non-small cell lung cancer (NSCLC) who developed RRP following administration of immune checkpoint inhibitor (ICI) 18 months after the end of re-irradiation. CASE PRESENTATION: A 69-year-old man received adjuvant chemoradiotherapy post-operatively. He underwent thoracic re-irradiation for oligometastatic NSCLC. On second recurrence, pembrolizumab combined with nab-paclitaxel were administered. After six months, he developed symptoms of persistent cough and dyspnea, with consistent pneumonitis on CT images. The clinical time frame and significant radiographic evidence raised suspicion for RRP. Symptoms resolved after steroids.

conclusionsRRP is a rare occurrence. Patients undergoing immunotherapy after prior irradiation may be at increased risk of this rare radiation pneumonitis.

Indexed as

AgedAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChinaCombined Modality TherapyHumansImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsLymphatic MetastasisMaleNeoplasm Recurrence, LocalRadiation PneumonitisRe-IrradiationTreatment OutcomeAntineoplastic AgentsImmune Checkpoint InhibitorsImmunotherapyNSCLCRadiation recall pneumonitisRadiotherapy

Identifiers

PMID35123465
PMCPMC8817644
OpenAlexW4213328452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.